{
    "ticker": "CINGW",
    "name": "Cingulate, Inc.",
    "description": "Cingulate, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for Attention Deficit Hyperactivity Disorder (ADHD) and related conditions. Founded in 2017, Cingulate is dedicated to improving the lives of patients by providing effective, non-stimulant therapies that address unmet medical needs in the ADHD market. The company's proprietary drug delivery technology, known as the Cingulate platform, allows for the creation of formulations that provide consistent therapeutic effects throughout the day. Cingulate's lead product candidate, Cingulate XR, is a once-daily, extended-release formulation designed to optimize the management of ADHD symptoms while minimizing side effects often associated with traditional stimulant medications. The company is committed to conducting rigorous clinical trials to ensure the safety and efficacy of its products and is actively working to expand its pipeline with additional candidates for ADHD and potentially other neurodevelopmental disorders. With a strong emphasis on patient-centric solutions, Cingulate aims to collaborate with healthcare professionals and stakeholders to enhance treatment options and improve patient outcomes in the ADHD community.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "Kansas City, Missouri, USA",
    "founded": "2017",
    "website": "https://www.cingulate.com",
    "ceo": "Shawn F. McCulley",
    "social_media": {
        "twitter": "https://twitter.com/CingulateInc",
        "linkedin": "https://www.linkedin.com/company/cingulate/"
    },
    "investor_relations": "https://ir.cingulate.com",
    "key_executives": [
        {
            "name": "Shawn F. McCulley",
            "position": "CEO"
        },
        {
            "name": "James A. Kauffman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Cingulate XR"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cingulate, Inc. | Innovative ADHD Treatments",
        "meta_description": "Learn about Cingulate, Inc., a biopharmaceutical company dedicated to developing innovative, non-stimulant treatments for ADHD. Explore our technology and pipeline.",
        "keywords": [
            "Cingulate",
            "ADHD",
            "Biopharmaceutical",
            "Cingulate XR",
            "Healthcare"
        ]
    },
    "faq": [
        {
            "question": "What is Cingulate known for?",
            "answer": "Cingulate is known for developing innovative treatments for ADHD, particularly its lead product candidate, Cingulate XR."
        },
        {
            "question": "Who is the CEO of Cingulate?",
            "answer": "Shawn F. McCulley is the CEO of Cingulate, Inc."
        },
        {
            "question": "Where is Cingulate headquartered?",
            "answer": "Cingulate is headquartered in Kansas City, Missouri, USA."
        },
        {
            "question": "What is Cingulate XR?",
            "answer": "Cingulate XR is a once-daily, extended-release formulation designed to manage ADHD symptoms effectively."
        },
        {
            "question": "When was Cingulate founded?",
            "answer": "Cingulate was founded in 2017."
        }
    ],
    "competitors": [
        "ADHD",
        "PTCT",
        "AXGT",
        "VYGR"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRK",
        "ABBV"
    ]
}